These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38907947)

  • 1. What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
    Bellitto C; Luxi N; Ciccimarra F; L'Abbate L; Raethke M; van Hunsel F; Lieber T; Mulder E; Riefolo F; Villalobos F; Thurin NH; Marques FB; Morton K; O'Shaughnessy F; Sonderlichová S; Farcas A; Janneke GE; Sturkenboom MC; Trifirò G
    Drug Saf; 2024 Jun; ():. PubMed ID: 38907947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study.
    Ciccimarra F; Luxi N; Bellitto C; L'Abbate L; Raethke M; van Hunsel F; Lieber T; Mulder E; Riefolo F; Dureau-Pournin C; Farcas A; Batel Marques F; Morton K; Roy D; Sonderlichová S; Thurin NH; Villalobos F; Sturkenboom MC; Trifirò G
    Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Raethke M; van Hunsel F; Luxi N; Lieber T; Bellitto C; Mulder E; Ciccimarra F; Riefolo F; Thurin NH; Roy D; Morton K; Villalobos F; Batel Marques F; Farcas A; Sonderlichová S; Belitser S; Klungel O; Trifirò G; Sturkenboom MC
    Vaccine; 2024 Apr; 42(9):2357-2369. PubMed ID: 38448322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Raethke M; van Hunsel F; Thurin NH; Dureau-Pournin C; Mentzer D; Kovačić B; Mirošević Skvrce N; De Clercq E; Sabbe M; Trifirò G; Luxi N; Giovanazzi A; Shakir S; Klungel OH; Schmikli S; Sturkenboom M
    Drug Saf; 2023 Apr; 46(4):391-404. PubMed ID: 37024736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
    Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
    Ahmadizar F; Luxi N; Raethke M; Schmikli S; Riefolo F; Saraswati PW; Bucsa C; Osman A; Liddiard M; Maques FB; Petrelli G; Sonderlichová S; Thurin NH; Villalobos F; Trifirò G; Sturkenboom M;
    Drug Saf; 2023 Jun; 46(6):575-585. PubMed ID: 37103643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study.
    Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D
    Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Adverse Reactions of Pfizer BioNTech COVID-19 Vaccine Booster Dose are Mild and Similar to the Second Dose Responses: A Retrospective Cross-Sectional Study.
    El-Shitany NA; Bagher AM; Binmahfouz LS; Eid BG; Almukadi H; Badr-Eldin SM; El-Hamamsy M; Mohammedsaleh ZM; Saleh FM; Almuhayawi MS; Alghamdi SA; Arab RA; Ali SS; Harakeh S; Alghamdi BS
    Int J Gen Med; 2022; 15():6821-6836. PubMed ID: 36051568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.
    Nafar M; Mostafaloo N; Firouzan A; Poorrezagholi F; Samadian F; Dalili N; Barati S; Anjidani N; Kafi H; Shahpari R; Bayat M; Kianipour S; Samavat S
    Clin Ther; 2022 Dec; 44(12):1566-1576. PubMed ID: 36402595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt JG; Thompson D; Su JR; Myers TR; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(28):899-903. PubMed ID: 35834416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.